U.S. flag An official website of the United States government
  1. Home
  2. Drug Databases
  3. Orange Book Home

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Home | Back to Search Results

Product Details for NDA 022522

Expand all

DALIRESP (ROFLUMILAST)
250MCG
Marketing Status: Prescription
Active Ingredient: ROFLUMILAST
Proprietary Name: DALIRESP
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 250MCG
Reference Listed Drug: Yes
Reference Standard: No
TE Code: 
Application Number: N022522
Product Number: 002
Approval Date: Jan 23, 2018
Applicant Holder Full Name: ASTRAZENECA PHARMACEUTICALS LP
Marketing Status:  Prescription
Patent and Exclusivity Information
DALIRESP (ROFLUMILAST)
500MCG
Marketing Status: Prescription
Active Ingredient: ROFLUMILAST
Proprietary Name: DALIRESP
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 500MCG
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code: AB
Application Number: N022522
Product Number: 001
Approval Date: Feb 28, 2011
Applicant Holder Full Name: ASTRAZENECA PHARMACEUTICALS LP
Marketing Status:  Prescription
Patent and Exclusivity Information
Back to Top